Cargando…

Antidepressant medication treatment patterns in Asian patients with major depressive disorder

PURPOSE: To describe pharmacological treatment patterns in Asian patients with major depressive disorder (MDD), including duration of treatment, reasons for medication discontinuation, rate of medication nonadherence, factors associated with medication nonadherence, and impact of medication nonadher...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novick, Diego, Montgomery, William, Moneta, Victoria, Peng, Xiaomei, Brugnoli, Roberto, Haro, Josep Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362981/ https://www.ncbi.nlm.nih.gov/pubmed/25792815 http://dx.doi.org/10.2147/PPA.S68432

Ejemplares similares

Do concomitant pain symptoms in patients with major depression affect quality of life even when taking into account baseline depression severity?
por: Novick, Diego, et al.
Publicado: (2013)

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
por: Novick, Diego, et al.
Publicado: (2016)

Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study
por: Novick, Diego, et al.
Publicado: (2017)

Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East
por: Hong, Jihyung, et al.
Publicado: (2017)

Impact of anxiety symptoms on outcomes of depression: an observational study in Asian patients
por: Novick, Diego, et al.
Publicado: (2016)

Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
por: Hong, Jihyung, et al.
Publicado: (2015)

Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
por: Novick, Diego, et al.
Publicado: (2015)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018)

Sex differences in the course of schizophrenia across diverse regions of the world
por: Novick, Diego, et al.
Publicado: (2016)

Should Unexplained Painful Physical Symptoms be Considered within the Spectrum of Depressive Symptoms?
por: Hong, Jihyung, et al.
Publicado: (2015)

Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study
por: Hong, Jihyung, et al.
Publicado: (2012)

Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study
por: Novick, Diego, et al.
Publicado: (2015)

Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study
por: Brugnoli, Roberto, et al.
Publicado: (2012)

Should antidepressants be used for major depressive disorder?
por: Jakobsen, Janus Christian, et al.
Publicado: (2020)

Predictors and consequences of adherence to the treatment of pediatric patients with attention-deficit/hyperactivity disorder in Central Europe and East Asia
por: Hong, Jihyung, et al.
Publicado: (2013)

Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder
por: Novick, Diego, et al.
Publicado: (2017)

Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis
por: Kato, Masaki, et al.
Publicado: (2020)

Patient characteristics associated with treatment initiation among paediatric patients with Attention-Deficit/Hyperactivity Disorder symptoms in a naturalistic setting in Central Europe and East Asia
por: Hong, Jihyung, et al.
Publicado: (2014)

Network analysis of the depressive symptom profiles in Asian patients with depressive disorders: Findings from the Research on Asian Psychotropic Prescription Patterns for Antidepressants (REAP‐AD)
por: Park, Seon‐Cheol, et al.
Publicado: (2020)

Mental Disorders, Musculoskeletal Disorders and Income-Driven Patterns: Evidence from the Global Burden of Disease Study 2017
por: Tyrovolas, Stefanos, et al.
Publicado: (2020)

Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment
por: Leutner, Michael, et al.
Publicado: (2021)

Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment
por: Garcia-Toro, Mauro, et al.
Publicado: (2012)

What factors explain the changes in major depressive disorder symptoms by age group during the COVID-19 pandemic? A longitudinal study
por: Gabarrell-Pascuet, Aina, et al.
Publicado: (2023)

ARPNet: Antidepressant Response Prediction Network for Major Depressive Disorder
por: Chang, Buru, et al.
Publicado: (2019)

Corrigendum: Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment
por: Leutner, Michael, et al.
Publicado: (2021)

Association of depressive disorders, depression characteristics and antidepressant medication with inflammation
por: Vogelzangs, N, et al.
Publicado: (2012)

Quantifying the level of difficulty to treat major depressive disorder with antidepressants: Treatment Resistance to Antidepressants Evaluation Scale
por: Liu, Tzu-Yu, et al.
Publicado: (2020)

The Use of Antidepressant Drugs and the Lifetime Prevalence of Major Depressive Disorders in Italy
por: Carta, Mauro Giovanni, et al.
Publicado: (2010)

Medication Adherence and Persistence in Patients with Severe Major Depressive Disorder with Psychotic Features: Antidepressant and Second-Generation Antipsychotic Therapy Versus Antidepressant Monotherapy
por: Kim-Romo, Dawn N., et al.
Publicado: (2016)

New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
por: Katona, Cornelius L, et al.
Publicado: (2014)

Pro-Inflammatory Cytokines as Predictors of Antidepressant Effects of Exercise in Major Depressive Disorder
por: Rethorst, Chad D., et al.
Publicado: (2012)

Antidepressants normalize elevated Toll-like receptor profile in major depressive disorder
por: Hung, Yi-Yung, et al.
Publicado: (2015)

Times to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive Disorder
por: Jung, Woo-Young, et al.
Publicado: (2016)

Serum Cytokine Levels in Major Depressive Disorder and Its Role in Antidepressant Response
por: Myung, Woojae, et al.
Publicado: (2016)

Exploring the Role of Gut Microbiota in Major Depressive Disorder and in Treatment Resistance to Antidepressants
por: Fontana, Andrea, et al.
Publicado: (2020)

Transcranial Magnetic Stimulation Markers of Antidepressant Treatment in Adolescents With Major Depressive Disorder
por: Doruk Camsari, Deniz, et al.
Publicado: (2019)

Increased Cortical Thickness in Patients With Major Depressive Disorder Following Antidepressant Treatment
por: Nemati, Samaneh, et al.
Publicado: (2020)

Potential of Antithrombin III as a Biomarker of Antidepressive Effect in Major Depressive Disorder
por: Song, Ruize, et al.
Publicado: (2021)

Effects of Antidepressant Treatment on Peripheral Biomarkers in Patients with Major Depressive Disorder (MDD)
por: Mosiołek, Anna, et al.
Publicado: (2021)

Potential of antithrombin III as a biomarker of antidepressive effect in major depressive disorder
por: Song, R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lvu6cr018gq1vlf5de81ld5crt